Logo Università degli Studi di Milano


Marie Skłodowska-Curie ITN-European Joint Doctorate MOGLYNET-PhD programme in DRUG DISCOVERY AND DEVELOPMENT: Open call 25 September-25 October 2015

Moglynet dottorato

Our Department will take part in the Horizon 2020-funded joint doctoral project MOGLYNET (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”), coordinated by the Prof. Luisa Gelmi (University of Milan).

The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies: Computational chemistry, Chemical synthesis, Bioanalytics and biophysics, In vitro biological evaluation, In vivo studies, Imaging, Metabolomics, Proteomics.

12 positions are currently available at the Universities of Milan, Antwerp, Aberdeen, Barcelona, Leiden (please see the flyer). The candidates will be recruited starting from February 2016.

More details concerning the project and application rules can be found in Moglynet web-site www.moglynet.com

For any doubt contact us!

marialuisa.gelmi@unimi.it (coordinator)

MoGlyNet PhD programme aims to define a joint doctorate educational training model inDrug Discovery and Development.

An active contribution of Industry in training activities is an important feature of the programme.

Research methodology and approachproposed by the MoGlyNet consortium is strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies. 


→ University of Milan (Pharmaceutical Sciences and Pharmacological and Biomolecular Sciences Departments), Italy – Coordinating University

→ University of Aberdeen (Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition) UK

→ University of Antwerp (Laboratory of Physiopharmacology), Belgium

→ University of Barcelona (Department of Biochemistry and Molecular Biology), Spain

→ University of Leiden (Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine), The Netherlands


→ Bayer Health Care Pharmaceuticals, Italy

→ Biomax Informatics AG, Germany

→ HistoGeneX N.V., Belgium

→ KemoTech Srl, Italy

→ Linkcare Health Services, Spain

→ PharmintracoSagl, Switzerland

→ PPD Italy srl, Italy


→ EIPG (European Industrial Pharmacists Group)

→ EAS (European Atherosclerosis Society)

→ EDQM (European Directorate for the Quality of Medicines)


University of Milan: Pharmaceutical Sciences

University of Milan: Pharmacological Experimental and Clinical Sciences

University of Aberdeen:  Graduate School in Life Sciences and Medicine

University of Antwerp:  Antwerp Doctoral School

University of Barcelona Doctoral School

University of Leiden: Graduate School of Leiden University Medical Center









MOGLYNET research fields:

  • Modulation of glycolytic enzymes activity as a therapeutic strategy to control atherogenesis and plaque rupture
  • Development of new activators of specific glycolytic enzymes activity as a new strategy to control atherogenesis
  • Studies on the role of glycolytic enzyme modulators and other glycolytic pathway flux key players in endothelial dysfunctionality associated to comorbidities in patients with atherosclerosis

 Basing on these research fields, Applicants are requested to choose among 12 different and multidisciplinary projects strongly related each other involving different state-of-the-art technologies and methodologies:

  • Computational chemistry
  • Chemical synthesis
  • Bioanalytics and biophysics
  • In vitro biological evaluation
  • In vivo studies
  • Imaging
  • Metabolomics
  • Proteomics
  • Oxidative stress


Why should YOU participate in MOGLYNET programme?

-  Cutting-edge research on Drug Discovery and Development

-  Top research centers in Europe

-  Interdisciplinary programmes

-  Advanced courses; summer schools; seminars

-  Critical “pharma skills” learning

-  International mobility plan

-  Stage Scholarship opportunities in Industry


Who can apply?

  • 2nd Level Master Degree (120 ECTS + 180 ECTS in a bachelor degree) or Single Cycle Degree (minimum 300 ECTS), or comparable university degree (Second Cycle qualification) graduate students from all over the world.
  • Graduate students in the fields of chemistry, medicinal chemistry, pharmacology, biochemistry, biomedical and biopharmaceutical sciences, medicine


What does the scholarship cover?

The PhD Candidate will receive a 36-month grant to cover the participation costs, living, travel and installation allowance, as follows:

Living allowance

€  3,110/montha,b

Mobility allowance

€  600/month

Family allowance

€  500/monthc

Total grant (36 months) a,b,c

€ 151,560

aThis amount is then adjusted through the application of a correction coefficient to the living allowance of the country in which the researcher will be recruited. bThe living allowance is a gross EU contribution to the salary costs of the researcher. Consequently, the net salary results from deducting all compulsory (employer/employee) social security contributions as well as direct taxes (e.g. income tax) from the gross amounts. cThe family allowance will be paid should the researcher have family.

14 September 2015
Back to top